source
- Novartis stops ALS TREM2 stabilizer after Phase 2 miss, marking fourth trial setback in a monthNovartis has halted development of its TREM2 stabilizer VHB937, also known as lifonebart, for amyotrophic lateral sclerosis after the drug failed to meet either the primary or secondary endpoints i…
- Biopharma workers increasingly postpone retirement, poll shows 52% plan to stay longerBiopharma professionals are rethinking retirement, with a BioSpace LinkedIn poll indicating that 52% expect to retire later than originally planned. Overall, 63% of respondents said they have chang…